%0 Journal Article
%T Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design
%A Allan D. Struthers
%A Amir Fathi
%A Chim C. Lang
%A Ewan R. Pearson
%A Ify Mordi
%A J. Graeme Houston
%A Jagdeep S. S. Singh
%A Keeran Vickneson
%A Mohapradeep Mohan
%J Archive of "Cardiovascular Diabetology".
%D 2016
%R 10.1186/s12933-016-0419-0
%X Heart failure (HF) and diabetes (DM) are a lethal combination. The current armamentarium of anti-diabetic agents has been shown to be less efficacious and sometimes even harmful in diabetic patients with concomitant cardiovascular disease, especially HF. Sodium glucose linked co-transporter type 2 (SGLT2) inhibitors are a new class of anti-diabetic agent that has shown potentially beneficial cardiovascular effects such as pre-load and after load reduction through osmotic diuresis, blood pressure reduction, reduced arterial stiffness and weight loss. This has been supported by the recently published EMPA-REG trial which showed a striking 38 and 35 % reduction in cardiovascular death and HF hospitalisation respectively
%K Heart failure
%K Diabetes
%K SGLT2 inhibitor
%K Mechanistic trial
%K Cardiac MRI
%K Cardiopulmonary exercise testing
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946228/